

Available online at www.sciencedirect.com

### **ScienceDirect**



journal homepage: www.e-jds.com

Original Article

# Anemia, hematinic deficiencies, and hyperhomocysteinemia in male and female burning mouth syndrome patients



Yu-Hsueh Wu<sup>a,b†</sup>, Ying-Tai Jin<sup>c,d†</sup>, Yang-Che Wu<sup>e,f</sup>, Julia Yu-Fong Chang<sup>g,h,i</sup>, Chun-Pin Chiang<sup>g,h,i,j\*</sup>, Andy Sun<sup>g,h,i\*\*</sup>

- <sup>a</sup> Department of Stomatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
- <sup>b</sup> Institute of Oral Medicine, School of Dentistry, National Cheng Kung University, Tainan, Taiwan
- <sup>c</sup> Department of Pathology, Taiwan Adventist Hospital, Taipei, Taiwan
- <sup>d</sup> Department of Pathology, National Cheng Kung University Hospital, Tainan, Taiwan
- <sup>e</sup> School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan
- <sup>f</sup> Department of Dentistry, Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan
- <sup>g</sup> Department of Dentistry, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan
- <sup>h</sup> Graduate Institute of Oral Biology, School of Dentistry, National Taiwan University, Taipei, Taiwan
- <sup>i</sup> Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan
- <sup>j</sup> Department of Dentistry, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan

Received 25 November 2021 Available online 9 December 2021

KEYWORDS Burning mouth syndrome; Hemoglobin; Iron; Vitamin B12;	Abstract Background/purpose: Our previous study found that 19.8%, 16.2%, 4.8%, 2.3%, 19.2%, and 12.3% of 884 burning mouth syndrome (BMS) patients have anemia, serum iron, vitamin B12, and folic acid deficiencies, hyperhomocysteinemia, and serum gastric parietal cell antibody (GPCA) positivity, respectively. This study mainly evaluated the anemia, hematinic deficiencies, and hyperhomocysteinemia in 212 male and 672 female BMS patients. Materials and methods: The blood hemoglobin (Hb) and serum iron, vitamin B12, folic acid,
--	---

\* Corresponding author. Department of Dentistry, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 707, Section 3, Chung-Yang Road, Hualien 970, Taiwan. Fax: +886 2 2389 3853

\*\* Corresponding author. Department of Dentistry, National Taiwan University Hospital, No. 1, Chang-Te Street, Taipei 10048, Taiwan. Fax: +886 2 2389 3853

E-mail addresses: cpchiang@ntu.edu.tw (C.-P. Chiang), andysun7702@yahoo.com.tw (A. Sun).

<sup>†</sup> These two authors contributed equally to this work.

#### https://doi.org/10.1016/j.jds.2021.11.017

1991-7902/© 2021 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Folic acid; Homocysteine	homocysteine, GPCA levels in 212 male and 672 female BMS patients were measured and compared with the corresponding levels in 106 male and 336 female healthy control subjects, respectively. <i>Results:</i> We found that 212 male BMS patients had significantly lower mean blood Hb, serum iron, vitamin B12, and folic acid levels and significantly higher mean serum homocysteine levels than 106 male healthy control subjects. Moreover, 672 female BMS patients had signif- icantly lower mean blood Hb and serum iron levels and significantly higher mean serum homo- cysteine level than 336 female healthy control subjects. In addition, 212 male BMS patients had significantly higher mean blood Hb and serum homocysteine levels, significantly lower mean serum vitamin B12 and folic acid levels, and significantly higher frequencies of folic acid deficiency and hyperhomocysteinemis than 672 female BMS patients. <i>Conclusion:</i> The male BMS patients do have significantly higher mean blood Hb and serum ho- mocysteine levels, significantly lower mean serum vitamin B12 and folic acid deficiency and hyperhomocysteinemis than 672 female BMS patients.
	© 2021 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons. org/licenses/by-nc-nd/4.0/).

#### Introduction

Burning mouth syndrome (BMS) is characterized by the presence of burning sensation of the oral mucosa in the absence of clinically apparent mucosal alterations. It occurs more commonly in the middle-aged and elderly women and the prevalence of BMS increases with advancing age. BMS can be classified into two clinical forms: primary and secondary BMS. The primary BMS is essential or idiopathic, in which the organic local/systemic causes cannot be identified, and peripheral and central neuropathological pathways are involved. The secondary BMS is caused by local, systemic, and/or psychological factors.<sup>1,2</sup>

In our oral mucosal disease clinic, BMS patients are relatively frequently encountered.<sup>1–11</sup> Our previous study of 884 BMS patients found that all of them complained of burning sensation at some sites of oral mucosa, especially the tip and lateral borders of the tongue and anterior hard palate. Moreover, dry mouth, numbness of oral mucosa, and dysfunction of taste can be observed in 48.1%, 30.7% and 16.7% of 884 BMS patients.<sup>2</sup> We also discovered that 19.8%, 16.2%, 4.8%, 2.3%, 19.2%, and 12.3% of 884 BMS patients have anemia, serum iron, vitamin B12, and folic acid deficiencies, hyperhomocysteinemia, and serum gastric parietal cell antibody (GPCA) positivity, respectively.<sup>2</sup> In another our previous study, 399 primary and secondary BMS patients without or with hematinic deficiencies were treated with vitamin BC capsules plus none, one, or two deficient hematinics depending on the corresponding deficiency statuses of the patients. Of the 399 BMS patients, 177 (44.4%) showed complete remission of all oral symptoms after treatment.<sup>11</sup> To the best of our knowledge, none of previous studies compared the complete blood count data, serum iron, vitamin B12, folic acid, homocysteine, and GPCA levels between a large group of male and female BMS patients. Therefore, in this study, we divided the 884 BMS patients into 212 male and 672 female BMS patients.

We mainly evaluated whether 212 male BMS patients had significantly lower frequencies of blood hemoglobin (Hb) and serum iron, vitamin B12, and folic acid deficiencies, hyperhomocysteinemia, and serum GPCA positivity than 672 female BMS patients. We also assessed whether there were significantly higher frequencies of blood Hb and serum iron, vitamin B12, and folic acid deficiencies, hyperhomocysteinemia, and serum GPCA positivity in 212 male and 672 female BMS patients than in 106 male and 336 female healthy control subjects, respectively.

#### Materials and methods

#### Participants

This study included 212 male BMS patients (age range 18–88 years, mean 53.3  $\pm$  16.9 years) and 672 female BMS patients (age range 18–90 years, mean 57.0  $\pm$  13.5 years).<sup>2</sup> For two BMS patients, one age-  $(\pm 2$  years of each patient's age) and sex-matched healthy control subject was selected. Thus, 106 male (age range 20-90 years, mean 54.5  $\pm$  14.7 years) and 336 female (age range 18–88 years, mean 58.5  $\pm$  13.0 years) age- and sex-matched healthy control subjects were selected and included in this study.<sup>2</sup> All the patients and control subjects were seen consecutively, diagnosed, and treated in the Department of Dentistry of National Taiwan University Hospital (NTUH) from July 2007 to July 2017. The detailed inclusion and exclusion criteria for 884 BMS patients and 442 healthy control subjects have been described previously.<sup>2</sup> In addition, none of the BMS patients had taken any prescription medication for BMS at least 3 months before entering the study.

The blood samples were drawn from 884 BMS patients and 442 healthy control subjects for the measurement of complete blood count, serum iron, vitamin B12, folic acid, and homocysteine concentrations, and the serum GPCA positivity. All BMS patients and healthy control subjects signed the informed consent forms before entering the study. This study was reviewed and approved by the Institutional Review Board at the NTUH (201212066RIND).

Determination of blood hemoglobin, iron, vitamin B12, folic acid, and homocysteine concentrations.

The complete blood count and serum iron, vitamin B12, folic acid, and homocysteine concentrations were determined by the routine tests performed in the Department of Laboratory Medicine, NTUH.  $^{1-11}$ 

## Determination of serum gastric parietal cell antibody level

The serum GPCA level was detected by the indirect immunofluorescence technique with rat stomach as a substrate as described previously.<sup>2–10</sup> Sera were scored as positive when they produced fluorescence at a dilution of 10-fold or more.

#### Statistical analysis

Comparisons of the mean corpuscular volume (MCV) and mean blood Hb and serum iron, vitamin B12, folic acid, and homocysteine levels between 212 male or 672 female BMS patients and 106 male or 336 female healthy control subjects, respectively, as well as between 212 male and 672 female BMS patients were performed by Student's t-test. The differences in frequencies of microcytosis (MCV <80 fL),<sup>12,13</sup> macrocytosis (MCV  $\geq$ 100 fL),<sup>14–16</sup> blood Hb and serum iron, vitamin B12, and folic acid deficiencies, hyperhomocysteinemia, and serum GPCA positivity between 212 male or 672 female BMS patients and 106 male or 336 female healthy control subjects, respectively, as well as between 212 male and 672 female BMS patients were compared by chi-square test. In addition, the differences in frequencies of 6 different types of anemia between 212 male and 672 female BMS patients were also compared by chi-square test. The result was considered to be significant if the P-value was less than 0.05.

#### Results

The MCV, mean blood Hb and serum iron, vitamin B12, folic acid, and homocysteine levels in 212 male and 672 female BMS patients and in 106 male and 336 female healthy control subjects are shown in Table 1. We found that 212 male BMS patients had significantly lower mean blood Hb, serum iron, vitamin B12, and folic acid levels and significantly higher mean serum homocysteine levels than 106 male healthy control subjects (all P-values < 0.05, Table 1). Moreover, 672 female BMS patients had significantly lower MCV and mean blood Hb and serum iron levels, and significantly higher mean serum homocysteine level than 336 female healthy control subjects (all *P*-values < 0.05, Table 1). In addition, 212 male BMS patients had significantly lower mean serum vitamin B12 and folic acid levels and significantly higher mean blood Hb and serum homocysteine levels than 672 female BMS patients (all *P*-values < 0.001,

Table 1). However, no significant difference in the MCV and mean serum iron level was found between 212 male and 672 female BMS patients (Table 1).

According to the World Health Organization (WHO) criteria, microcytosis of erythrocyte was defined as having MCV < 80 fL.<sup>12,13</sup> macrocytosis of erythrocyte was defined as having MCV >100 fL,  $^{14-16}$  and men with Hb < 13 g/dL and women with Hb < 12 g/dL were defined as having Hb deficiency or anemia.<sup>17</sup> Furthermore, patients with the serum iron level  $<60 \ \mu$ g/dL,<sup>18</sup> the serum vitamin B12 level  $<200 \$ g/ mL,<sup>19</sup> or the folic acid level <4 ng/mL<sup>20</sup> were defined as having serum iron, vitamin B12 or folic acid deficiency. respectively. In addition, patients with the blood homocysteine level  $>12.3 \ \mu$ M (which was the mean serum homocysteine level of healthy control subjects plus two standard deviations) were defined as having hyperhomocysteinemia.<sup>2</sup> By the above-mentioned definitions, 5.2%, 7.1%, 18.9%, 13.2%, 5.2%, 4.7%, 32.5%, and 12.3% of 212 male BMS patients and 8.5%, 4.6%, 20.1%, 17.1%, 4.6%, 1.5%, 15.0%, and 12.4% of 672 female BMS patients were diagnosed as having microcytosis, macrocytosis, blood Hb and serum iron, vitamin B12, and folic acid deficiencies, hyperhomocysteinemia, and serum GPCA positivity, respectively (Table 2). Moreover, 212 male BMS patients had significantly higher frequencies of microcvtosis, macrocvtosis, blood Hb and serum iron, vitamin B12, and folic acid deficiencies, hyperhomocysteinemia, and serum GPCA positivity than 106 male healthy control subjects (all *P*-values < 0.05, Table 2). Furthermore, 672 female BMS patients had significantly higher frequencies of microcytosis, macrocytosis, blood Hb and serum iron and vitamin B12 deficiencies, hyperhomocysteinemia, and serum GPCA positivity than 336 female healthy control subjects (all *P*-values < 0.001, Table 2). In addition, 212 male BMS patients had significantly higher frequencies of folic acid deficiency and hyperhomocysteinemis than 672 female BMS patients (both Pvalues < 0.05, Table 2).

Forty male and 135 female BMS patients had anemia (defined as having an Hb concentration <13 g/dL for men and <12 g/dL for women).<sup>17</sup> Of the 40 anemic male BMS patients, 3 had pernicious anemia (PA, defined as having anemia, an MCV >100 fL, a serum vitamin B12 level <200 pg/mL, and the presence of serum GPCA positivity),<sup>14–16</sup> 7 had macrocytic anemia (defined as having anemia and an MCV  $\geq$ 100 fL) other than PA,<sup>14-16</sup> 26 had normocytic anemia (defined as having anemia and an MCV between 80 fL and 99.9 fL),<sup>21-24</sup> one had iron deficiency anemia (IDA, defined as having anemia, an MCV <80 fL, and a serum iron level <60  $\mu g/dL\bar{)},^{13,17,18}$  two had thalassemia trait-induced anemia (defined as having anemia, a red blood cell count  ${>}5.0$  M/µL, an MCV  ${<}74$  fL, and a Mentzer index (MCV/RBC) < 13),<sup>25</sup> and one had microcytic anemia (defined as having anemia and an MCV <80 fL)<sup>12,18</sup> other than IDA and thalassemia trait-induced anemia. Thus, by strict WHO criteria the normocytic anemia (65.0%, 26/40) was the most common type of anemia in our 40 anemic male BMS patients (Table 3).

Of the 135 anemic female BMS patients, 12 had PA,<sup>14–16</sup> 8 had macrocytic anemia other than PA,<sup>14–16</sup> 69 had normocytic anemia,<sup>21–24</sup> 20 had IDA,<sup>13,17,18</sup> 25 had thalassemia trait-induced anemia,<sup>25</sup> and one had microcytic anemia<sup>12,18</sup> other than IDA and thalassemia trait-induced anemia. Therefore, by strict WHO criteria the normocytic anemia (51.1%, 69/135), thalassemia trait-induced anemia (18.5%, 25/135), and IDA (14.8%, 20/135) were the three most

common types of anemia in our 135 anemic female BMS patients (Table 3). In addition, 672 female BMS patients had significantly higher frequency of thalassemia trait-induced anemia than 212 male BMS patients (P < 0.001, Table 3).

Table 1Comparisons of mean corpuscular volume (MCV) and mean blood hemoglobin (Hb) and serum iron, vitamin B12, folicacid, and homocysteine levels between 212 male or 672 female BMS patients and 106 male or 336 female healthy controlsubjects, respectively, as well as between 212 male BMS patients and 672 female BMS patients.

Group	MCV (fL)	Hb (g/dL)	lron (μg/dL)	Vitamin B12 (pg/mL)	Folic acid (ng/mL)	Homocysteine (µM)
Male BMS patients (n = $212$ )	$\textbf{90.2} \pm \textbf{7.0}$	$\textbf{14.6} \pm \textbf{1.5}$	$\textbf{92.4} \pm \textbf{26.8}$	$\textbf{545.3} \pm \textbf{256.6}$	$\textbf{11.6} \pm \textbf{6.3}$	$\textbf{11.2} \pm \textbf{5.7}$
<sup>a</sup> P-value <sup>b</sup> P-value	0.583 0.165	0.001 <0.001	<0.001 0.200	0.002 <0.001	0.027 <0.001	0.003 <0.001
Female BMS patients (n = 672) ${}^{a}P$ -value	89.4 ± 7.4 0.035	13.1 ± 1.2 <0.001	89.3 ± 31.8 <0.001	669.3 ± 264.9 0.343	$\begin{array}{c} \textbf{15.2} \pm \textbf{7.5} \\ \textbf{0.830} \end{array}$	8.7 ± 3.5 <0.001
Male healthy control subjects (n = 106)	90.6 ± 3.8	15.1 ± 0.8	105.2 ± 28.0	634.6 ± 210.9	13.2 ± 5.5	9.5 ± 1.8
Female healthy control subjects (n = 336)	90.3 ± 3.5	13.5 ± 0.7	97.8 ± 27.3	685.3 ± 225.4	15.1 ± 5.7	8.0 ± 2.0

<sup>a</sup> Comparisons of means of parameters between 212 male or 672 female BMS patients and 106 male or 336 female healthy control subjects by Student's *t*-test, respectively.

<sup>b</sup> Comparisons of means of parameters between 212 male BMS patients and 672 female BMS patients by Student's *t*-test.

**Table 2** Comparisons of frequencies of microcytosis (mean corpuscular volume or MCV <80 fL), macrocytosis (MCV  $\geq$ 100 fL), blood hemoglobin (Hb) and serum iron, vitamin B12, and folic acid deficiencies, and gastric parietal cell antibody (GPCA) positivity between 212 male or 672 female BMS patients and 106 male or 336 female healthy control subjects, respectively, as well as between 212 male BMS patients and 672 female BMS patients.

Group	Patient number (%)							
	•	$\begin{array}{l} \mbox{Macrocytosis} \\ \mbox{(MCV} \geq \! 100 \mbox{ fL}) \end{array}$	Hb deficiency (Men <13 g/dL, women <12 g/dL)	lron deficiency (<60 μg/dL)	Vitamin B12 deficiency (<200 pg/mL)	Folic acid deficiency (<4 ng/mL)	-cysteinemia	GPCA positivity
Male BMS patients (n = 212)	11 (5.2)	15 (7.1)	40 (18.9)	28 (13.2)	11 (5.2)	10 (4.7)	69 (32.5)	26 (12.3)
<sup>a</sup> P-value <sup>b</sup> P-value	0.039 0.155	0.012 0.219	<0.001 0.772	<0.001 0.215	0.039 0.874	0.053 0.013	<0.001 <0.001	0.004 0.931
Female BMS patients (n = 672) <sup>a</sup> P-value	57 (8.5) <0.001	31 (4.6)	135 (20.1) <0.001	115 (17.1) <0.001	31 (4.6)	10 (1.5) 0.056	101 (15.0) <0.001	83 (12.4)
Male healthy control subjects (n = 106)		0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.9)	2 (1.9)
Female healthy control subjects (n = 336)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	9 (2.7)	6 (1.8)

<sup>a</sup> Comparisons of frequencies of parameters between 212 male or 672 female BMS patients and 106 male or 336 female healthy control subjects by chi-square test, respectively.

<sup>b</sup> Comparisons of frequencies of parameters between 212 male BMS patients and 672 female BMS patients by chi-square test.

Table 3Comparison of frequencies of 6 different types of<br/>anemia between 212 male BMS patients and 672 female BMS<br/>patients.

Anemia type	Patient ı	<sup>a</sup> P-value	
	patients	Female BMS patients (n = 672)	
Pernicious anemia	3 (1.4)	12 (1.8)	0.953
Other macrocytic anemia	7 (3.3)	8 (1.2)	0.077
Normocytic anemia	26 (12.3)	69 (10.3)	0.489
Iron deficiency anemia	1 (0.5)	20 (3.0)	0.067
Thalassemia trait-induced anemia	2 (0.9)	25 (3.7)	<0.001
Other microcytic anemia	1 (0.5)	1 (0.1)	0.973
Total	40 (18.9)	135 (20.1)	0.772

<sup>a</sup> Comparison of frequencies of 6 different types of anemia between 212 male BMS patients and 672 female BMS patients by chi-square test.

#### Discussion

The major findings of this study were that the male BMS patients had significantly higher mean blood Hb and serum homocysteine levels, significantly higher frequencies of folic acid deficiency and hyperhomocysteinemis, and significantly lower mean serum vitamin B12 and folic acid levels than the female BMS patients. The male BMS patients also had higher mean serum iron level, higher frequency of vitamin B12 deficiency, and lower frequencies of Hb and serum iron deficiencies than the female BMS patients, but the differences were not significant between the male and female BMS patients.

Sex hormones can have a significant influence on the red blood cell, blood Hb, and serum iron levels.<sup>26-32</sup> Androgens can stimulate erythropoiesis and increase levels of red blood cells, hemoglobin, and hematocrit. Androgens stimulate hematopoietic system by various mechanisms, including stimulation of erythropoietin release, increase in bone marrow activity, and augmentation of iron incorporation into the red cells.26,27 Erythropoietin is a kidneyproduced hormone that stimulates the production and maintenance of red blood cells.28 However, in subjects with chronic mountain sickness (Monge's disease), estrogens have a striking negative effect on the erythropoietic response in a dose-dependent manner. Addition of estrogen at 5–10 nM (physiological estrogen levels: 0.1–10 nM) to erythroid cells isolated from females with chronic mountain sickness results in a significant decrease in red blood cell production, and the addition of estrogen at 50-100 nM leads to extremely low red blood cell production.29 In menopause women, estrogen decreases because of the cessation of ovarian functions and iron increases as a result of decreasing menstrual periods. Nevertheless, estrogen deficiency up-regulates hepcidin, which inhibits intestinal iron absorption, leading to lower serum iron levels.30 Therefore, the difference in the sex hormone levels between men and women can partially explain why men usually have higher blood Hb and serum iron levels.

In general, each healthy pregnancy depletes the mother of approximately 500 mg of iron. Menstrual blood losses are highly variable, ranging from 10 to 250 mL (4-100 mg of iron) per period. A man must absorb about 1 mg of iron to maintain equilibrium. During childbearing years, an adult female loses an average of 2 mg of iron daily and must absorb a similar quantity of iron in order to maintain equilibrium.<sup>31</sup> However, in the postmenopausal women, iron deficiency is uncommon in the absence of menstrual bleeding. Furthermore, because women eat less food than men, they must be more than twice as efficient as men in the absorption of iron to avoid iron deficiency. Therefore, anemia is twice as prevalent in females as in males.<sup>32</sup> This difference is significantly greater during the childbearing years due to pregnancies and menses.<sup>32</sup> Because our male BMS patients had a mean age of 53.3 years and the female BMS patients had a mean age of 57.0 years that was beyond the childbearing years, this could explain why the male BMS patients had higher mean serum iron level and lower frequencies of Hb and serum iron deficiencies than the female BMS patients.

We further explained why male BMS patients had the lower mean serum vitamin B12 and folic acid levels and higher frequencies of vitamin B12 and folic acid deficiencies than female BMS patients. Previous studies discovered significantly lower mean folate levels in buccal mucosal cells and sera of 25 smokers than in those of 34 non-smokers.<sup>33</sup> Pivathilake et al.<sup>34</sup> also demonstrated lower buccal mucosal cell folate and vitamin Bl2 concentrations in 39 current smokers than in 60 noncurrent smokers.<sup>34</sup> Our previous study of serum vitamin B12 and folic acid levels in oral precancer patients also found significantly lower mean serum folic acid levels in 87 cigarette smokers than in 44 non-smokers and in 26 smokers consuming >20 cigarettes per day than in 61 smokers consuming  $\leq$ 20 cigarettes per day.<sup>35</sup> The mean serum folic acid level was also lower in 52 betel quid chewers than in 79 non-chewers.<sup>35</sup> The findings of above-mentioned studies indicate the existence of vitamin B12 and folic acid deficiencies in the sera and oral mucosal cells of the smokers and betel quid chewers. We suggest that the mechanisms of vitamin B12 and folic acid deficiencies may arise from elevated vitamin B12 and folic acid consumption in response to rapid tissue proliferation or repair caused by the irritation or damage of oral mucosal cells by the carcinogens in tobacco or betel quid.<sup>36,37</sup> The present study found that male BMS patients had significantly lower mean serum vitamin B12 and folic acid levels and significantly higher frequency of folic acid deficiency than female BMS patients. Although male BMS patients had higher frequency of vitamin B12 deficiency than female BMS patients, the difference was not significant. In this study, we did not assess the frequencies of cigarette smoking and betel guid chewing habits in our 212 male and 672 female BMS patients. However, in the Taiwan population, the males  $\geq$ 18 years of age had a significantly higher prevalence of smoking habit (23.1% for men and 2.9% for women) or betel quid chewing habit (16.8% for men and 1.2% for women) than the females  $\geq 18$  years of age.<sup>38</sup> Because there is a significantly higher prevalence of smoking or betel guid chewing habit in men than in women in the Taiwan population, we strongly suggest that the smoking or betel quid chewing habit may be the major causes that result in the lower mean serum vitamin B12 and folic acid levels and higher frequencies of vitamin B12 and folic acid deficiencies in male BMS patients than in female BMS patients.

In this study, the normocytic anemia (65.0%, 26/40) was the most common type of anemia in our 40 anemic male BMS patients, followed by the other macrocytic anemia (17.5%, 7/40) and PA (7.5%, 3/40) (Table 3). Furthermore, the normocytic anemia (51.1%, 69/135), thalassemia traitinduced anemia (18.5%, 25/135), and IDA (14.8%, 20/135) were the three most common types of anemia in our 135 anemic female BMS patients (Table 3). From the abovementioned findings, we discovered that regardless of the normocytic anemia, the male BMS patients tended to have macrocytic anemia (PA and other macrocytic anemia) and the female BMS patients were prone to have microcytic anemia (thalassemia trait-induced anemia and IDA). As stated before, male BMS patients had the lower mean serum vitamin B12 and folic acid levels and higher frequencies of vitamin B12 and folic acid deficiencies than female BMS patients in the present study. Moreover, female BMS patients had the lower mean blood Hb and serum iron levels and higher frequencies of blood Hb and serum iron deficiencies than male BMS patients. These results could easy explain why the male BMS patients tended to have macrocytic anemia and the female BMS patients were prone to have microcytic anemia in the present study. In addition, this study also found that 672 female BMS patients had significantly higher frequency of thalassemia trait-induced anemia than 212 male BMS patients. The thalassemia trait-induced anemia is predominantly due to gene mutation resulting in insufficient production of either the  $\alpha$ globin or  $\beta$ -globin chains of the Hb molecule.<sup>25</sup> However, it needs further investigations to clarify the reasons why female BMS patients had significantly higher frequency of thalassemia trait-induced anemia than male BMS patients in the present study.

Homocysteine is formed during methionine metabolism.<sup>39</sup> Both vitamin B12 and folic acid function as coenzymes for the conversion of homocysteine to methionine.<sup>40</sup> Thus, patients with vitamin B12 and/or folic acid deficiencies may have hyperhomocysteinemia. A previous study has shown that a supplementation with folic acid and vitamins B12 and B6 can reduce blood homocysteine levels.<sup>41</sup> Our previous studies also demonstrated that supplementations with vitamin BC capsules plus corresponding deficient vitamin B12 and/or folic acid can reduce the abnormally high serum homocysteine level to significantly lower levels in patients with either atrophic glossitis or BMS.<sup>11,42</sup> In this study, significantly lower mean serum vitamin B12 and folic acid levels and higher frequencies of serum vitamin B12 and folic acid deficiencies in male BMS patients than in female BMS patients could explain why our male BMS patients had significantly higher mean serum homocysteine level and high frequency of hyperhomocysteinemia than our female BMS patients.

The results of this study conclude that the male BMS patients do have significantly higher mean blood Hb and serum homocysteine levels, significantly lower mean serum vitamin B12 and folic acid levels, and significantly higher frequencies of folic acid deficiency and hyper-homocysteinemis than the female BMS patients.

#### Declaration of competing interest

The authors have no conflicts of interest relevant to this article.

#### Acknowledgments

This study was partially supported by the grants (No. 102-2314-B-002-125-MY3 and No. 105-2314-B-002-075-MY2) of Ministry of Science and Technology, Taiwan.

#### References

- 1. Sun A, Wu KM, Wang YP, Lin HP, Chen HM, Chiang CP. Burning mouth syndrome: a review and update. *J Oral Pathol Med* 2013;42:649–55.
- Chiang CP, Wu YH, Wu YC, Chang JYF, Wang YP, Sun A. Anemia, hematinic deficiencies, hyperhomocysteinemia, and serum gastric parietal cell antibody positivity in 884 patients with burning mouth syndrome. J Formos Med Assoc 2020;119:813–20.
- Chiang CP, Wu YC, Wu YH, Chang JYF, Wang YP, Sun A. Gastric parietal cell and thyroid autoantibody in patients with burning mouth syndrome. J Formos Med Assoc 2020;119:1758–63.
- 4. Chiang ML, Wu YH, Chang JYF, Wang YP, Wu YC, Sun A. Anemia, hematinic deficiencies, and hyperhomocysteinemia in gastric parietal cell antibody-positive and -negative burning mouth syndrome patients. J Formos Med Assoc 2021;120:819–26.
- Chiang ML, Jin YT, Chiang CP, Wu YH, Chang JYF, Sun A. Anemia, hematinic deficiencies, hyperhomocysteinemia, and gastric parietal cell antibody positivity in burning mouth syndrome patients with vitamin B12 deficiency. *J Dent Sci* 2020; 15:34–41.
- Chiang ML, Chiang CP, Sun A. Anemia, hematinic deficiencies, and gastric parietal cell antibody positivity in burning mouth syndrome patients with or without hyperhomocysteinemia. J Dent Sci 2020;15:214–21.
- 7. Jin YT, Chiang ML, Wu YH, Chang JYF, Wang YP, Sun A. Anemia, hematinic deficiencies, hyperhomocysteinemia, and gastric parietal cell antibody positivity in burning mouth syndrome patients with iron deficiency. *J Dent Sci* 2020;15:42–9.
- Jin YT, Wu YC, Wu YH, Chang JYF, Chiang CP, Sun A. Anemia, hematinic deficiencies, hyperhomocysteinemia, and gastric parietal cell antibody positivity in burning mouth syndrome patients with or without microcytosis. J Dent Sci 2021;16:608–13.
- **9.** Jin YT, Wu YH, Wu YC, Chang JYF, Chiang CP, Sun A. Anemia, hematinic deficiencies, hyperhomocysteinemia, and gastric parietal cell antibody positivity in burning mouth syndrome patients with macrocytosis. *J Dent Sci* 2021;16:1133–9.
- **10.** Jin YT, Wu YH, Wu YC, Chang JYF, Chiang CP, Sun A. Anemia, hematinic deficiencies, and hyperhomocysteinemia in serum gastric parietal cell antibody-positive burning mouth syndrome patients without serum thyroid autoantibodies. *J Dent Sci* 2021;16:1110–6.
- **11.** Sun A, Lin HP, Wang YP, Chen HM, Cheng SJ, Chiang CP. Significant reduction of serum homocysteine level and oral symptoms after different vitamin supplement treatments in patients with burning mouth syndrome. *J Oral Pathol Med* 2013;42:474–9.
- 12. Lin HP, Wu YH, Wang YP, Wu YC, Chang JYF, Sun A. Anemia and hematinic deficiencies in gastric parietal cell antibody-positive and —negative oral mucosal disease patients with microcytosis. *J Formos Med Assoc* 2017;116:613–9.
- **13.** Wu YC, Wang YP, Chang JYF, Cheng SJ, Chen HM, Sun A. Oral manifestations and blood profile in patients with iron deficiency anemia. *J Formos Med Assoc* 2014;113:83–7.

- Sun A, Wang YP, Lin HP, Jia JS, Chiang CP. Do all the patients with gastric parietal cell antibodies have pernicious anemia? Oral Dis 2013;19:381–6.
- **15.** Sun A, Chang JYF, Wang YP, Cheng SJ, Chen HM, Chiang CP. Do all the patients with vitamin B12 deficiency have pernicious anemia? *J Oral Pathol Med* 2016;45:23–7.
- **16.** Chang JYF, Wang YP, Wu YC, Cheng SJ, Chen HM, Sun A. Hematinic deficiencies and pernicious anemia in oral mucosal disease patients with macrocytosis. *J Formos Med Assoc* 2015; 114:736–41.
- 17. WHO/UNICEF/UNU. Iron deficiency anaemia assessment, prevention, and control: a guide for programme managers. Geneva, Switzerland: World Health Organization, 2001.
- 18. Shine JW. Microcytic anemia. Am Fam Physician 1997;55: 2455-62.
- **19.** Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. *Am J Clin Nutr* 2007;85:193–200.
- de Benoist B. Conclusions of a WHO technical consultation on folate and vitamin B12 deficiencies. *Food Nutr Bull* 2008; 29(suppl):S238–44.
- 21. Brill JR, Baumgardner DJ. Normocytic anemia. *Am Fam Physician* 2000;62:2255–63.
- Koury MJ, Rhodes M. How to approach chronic anemia. Hematology Am Soc Hematol Educ Program 2012;2012:183–90.
- 23. Koury MJ. Abnormal erythropoiesis and the pathophysiology of chronic anemia. *Blood Rev* 2014;28:49–66.
- 24. Means Jr RT. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. *Stem Cell* 1995;13:32–7.
- 25. Wang YP, Chang JYF, Wu YC, Cheng SJ, Chen HM, Sun A. Oral manifestations and blood profile in patients with thalassemia trait. *J Formos Med Assoc* 2013;112:761–5.
- Shahani S, Braga-Basaria M, Maggio M, Basaria S. Androgens and erythropoiesis: past and present. J Endocrinol Invest 2009;32: 704–16.
- Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. *Blood* 2009;114:2236–43.
- Spivak JL. The mechanism of action of erythropoietin. Int J Cell Clon 1986;4:139–66.
- 29. Azad P, Villafuerte FC, Bermudez D, Patel G, Haddad GG. Protective role of estrogen against excessive erythrocytosis in Monge's disease. *Exp Mol Med* 2021;53:125–35.

- 30. Yang Q, Jian J, Katz S, Abramson SB, Huang X. 17β-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. *Endocrinology* 2012;153:3170–8.
- Medscape. Why is iron deficiency anemia more common in women than in men?. Available at: https://www.medscape. com/answers/202333-153111/why-is-iron-deficiencyanemia-more-common-in-women-than-in-men. [Accessed 12 November 2021].
- 32. Medscape. How does the prevalence of anemia vary between males and females?. Available at: https://www. medscape.com/answers/198475-155034/how-does-theprevalence-of-anemia-vary-between-males-and-females. [Accessed 12 November 2021].
- Piyathilake CJ, Hine RJ, Dasanayake AP, et al. Effect of smoking on folate levels in buccal mucosal cells. *Int J Cancer* 1992;52:566–9.
- Pivathilake CJ, Macaluso M, Hine RJ, Richards EW, Krumdieck CL. Local and systemic effects of cigarette smoking on folate and vitamin B-12. Am J Clin Nutr 1994;60:559–66.
- Wu YH, Wu YC, Chu FY, Cheng SJ, Sun A, Chen HM. Significantly higher frequencies of hematinic deficiencies and hyperhomocysteinemia in oral precancer patients. *J Formos Med Assoc* 2019;118:1299–307.
- 36. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194–210.
- **37.** Li WC, Lee PL, Chou IC, Chang WJ, Lin SC, Chang KW. Molecular and cellular cues of diet-associated oral carcinogenesis—with an emphasis on areca-nut-induced oral cancer development. *J Oral Pathol Med* 2015;44:167–77.
- **38.** Health Promotion Administration, Ministry of Health and Welfare. *The prevalences of smoking, betel quid chewing, and alcohol drinking habits in the population equal to or greater than 18 years old.* Taipei, Taiwan: Ministry of Health and Welfare, 2021.
- **39.** Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? *Lancet Neurol* 2007;6:830-8.
- 40. Chanarin I, Deacon R, Lumb M, Perry J. Cobalamin-folate interrelations. *Blood Rev* 1989;3:211-5.
- Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567–77.
- **42.** Sun A, Wang YP, Lin HP, Chen HM, Cheng SJ, Chiang CP. Significant reduction of homocysteine level with multiple B vitamins in atrophic glossitis patients. *Oral Dis* 2013;19:519–24.